Glenn P. Muir is a nominee to serve as a member of our Board. Mr. Muir served as Chief Financial Officer and Executive Vice President of Finance and Administration of Hologic, Inc., a publicly traded manufacturer and supplier of medical products, from 2000 until he retired in 2014. He also served as Hologic's Chief Financial Officer and Vice President of Finance and Administration from 1992 to 2000 and as Controller from 1988 to 1992. Prior to then, Mr. Muir served as Chief Financial Officer and Vice President of Finance and Administration at Metallon Engineered Materials Corp. from 1986 to 1988. He served as a Senior Auditor with Arthur Andersen & Co. from 1981 to 1984. Mr. Muir has served as a member of the board of directors of Repligen Corporation, a publicly traded life science company, since 2015 and as chair of its audit committee since 2016, and as a member of the board of directors of Neuronetics, Inc., a publicly traded medical technology company, since 2017 and as the current chair of its audit committee. Mr. Muir also served as a member of the board of directors of G1 Therapeutics, Inc., a publicly traded biotechnology company, from 2015 until September 2024, when it was acquired. He served as an independent director of ReWalk Robotics Ltd. and RainDance Technologies, Inc., both from 2014 to 2017. Mr. Muir holds a B.S. in Accounting from the University of Massachusetts in Amherst, an M.B.A. from the Harvard Business School, and an M. Sc. in Taxation from Bentley College Graduate School of Business. Mr. Muir previously obtained his certified public accountant license (inactive since 2022). We believe that Mr. Muir's extensive leadership and management experience in the biotechnology industry and financial expertise provide him with the qualifications and skills to serve as a director of the Company to contribute meaningfully as a member of the Audit Committee.